NetworkNewsBreaks – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) to Host August 8 Conference Call and Webcast to Discuss Q2 2019 Results

August 2, 2019 10:05:23

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) today announced that it will host a conference call and live audio webcast to provide a corporate update and discuss operational and financial results for the quarter ended June 30, 2019. The call is scheduled to be held at 8:30 a.m. Eastern Time on Thursday, August 8, 2019, and will be led by Corbus Chief Executive Officer Yuval Cohen, Ph.D., joined with additional members of the company’s management team. Interested participants and investors may access the call by dialing (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Corbus website, via the Events page of the Investors section, and will be archived for 90 days following the event.

To view the full press release, visit http://nnw.fm/Zb3gI

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory, fibrotic and metabolic diseases by leveraging its pipeline of endocannabinoid mimetic drug candidates. The Company’s lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (“CB2”) agonist designed to resolve inflammation and limit fibrosis. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (“CB1”) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (“NIH”)-funded proof-of-concept Phase 2 study. For more information, visit the company’s website at www.CorbusPharma.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com